STOCKHOLM, July 11, 2023 /PRNewswire/ — BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab, an anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.